-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Complicated urinary tract infection refers to the presence of acquired infection at the same time as the occurrence of urinary tract infection, or the failure of urinary tract infection treatment caused by structural and functional abnormalities such as bladder and ureter, which is likely to cause progressive decline in renal function due to repeated recurrence, which requires great attention
Tebipenem Pivoxil Hydrobromide is an oral bioavailable carbapenem antibiotic with activity against urinary tract pathogenic Enterobacter, including ultra-broad-spectrum β-lactamase and fluoroquinolone-resistant strains
In this international, double-blind, double-mock trial, patients were randomly assigned oral Tebipenem Pivoxil Hydrobromide (600 mg/8 hours) or intravenous ertapenem (1 g/24 hours) on a 1:1 ratio for 7 to 10 days (up to 14 days in patients with bacteremia).
A total of 1372 hospitalized adult patients were included, of which 868 (63.
efficacy
At THE TOC visit, the overall response rate of oral Tebipenem Pivoxil Hydrobromide was no less than that of intravenous ertapenem (58.
Table 1 Evaluation of efficacy of two sets of trials (number percentage shown)
At the TOC visit, similar microbiological responses were observed in the enterobacter pathogens in both treatment groups, and the TOC response rates of E.
security
The Tebipenem Pivoxil Hydrobromide and Enthapenem groups had 1 case (0.
1%) and 8 cases (1.
2%) of adverse events (AE)
of premature discontinuation of the test drug in the Tebipenem Pivoxil Hydrobromide and enthapenem groups, respectively.
Nine (1.
3%) and 12 (1.
7%) patients in both groups had at least one serious adverse event (SAE) (Table 2
).
The overall incidence of AE in both groups was 25.
7% and 25.
6%, respectively, with more than 1% of patients reporting AE as diarrhea, headache, and nausea, and most AE being mild or moderate in severity and non-therapeutic limitation
.
Table 2 Incidence of adverse reactions during the trial period
conclusion
Oral Tebipenem Pivoxil Hydrobromide is no less effective than intravenous ertapenem in patients with complicated urinary tract infection or acute pyelonephritis and has a similar safety profile
.
References:
1.
Meng Xianfeng,Zhang Zhe.
Research progress in the treatment of complicated urinary tract infections in traditional Chinese medicine[J].
Electronic Journal of Cardiovascular Diseases in Integrated Traditional Chinese and Western Medicine,2019,7(33):10+19.
2.
Eckburg PB, Muir L, Critchley IA, et al.
Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection.
N Engl J Med.
2022 Apr 7; 386(14):1327-1338.